Dr. Gerald Falchook, MD
Claim this profileSarah Cannon Research Institute at HealthONE
Area of expertise
Solid Tumors
Gerald Falchook, MD has run 20 trials for Solid Tumors. Some of their research focus areas include:
Cancer
Gerald Falchook, MD has run 18 trials for Cancer. Some of their research focus areas include:
Affiliated Hospitals
Sarah Cannon Research Institute At HealthONE
Sarah Cannon Research Institute
Clinical Trials Gerald Falchook, MD is currently running
GSK5764227
for Advanced Cancer
The goal of this study is to assess the safety, tolerability, clinical activity and pharmacokinetics of GSK5764227. The study will also see how the levels of GSK5764227 will change over time at different dose amounts when administered alone and in combination with other medicines like carboplatin, cisplatin, atezolizumab, pembrolizumab, durvalumab, bevacizumab, cetuximab.
Recruiting
1 award
Phase 1
2 criteria
LY4050784
for Advanced Cancer
The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMARCA4) alteration who have previously received, do not qualify for, or are refusing standard of care treatments, or there is no standard therapy available for the disease. The study is conducted in two parts - phase Ia (dose-escalation) and phase Ib (dose-optimization, dose-expansion). The study will last up to approximately 4 years.
Recruiting
1 award
Phase 1
2 criteria
More about Gerald Falchook, MD
Clinical Trial Related
7 years of experience running clinical trials · Led 40 trials as a Principal Investigator · 11 Active Clinical Trials
Treatments Gerald Falchook, MD has experience with
- Pembrolizumab
- Nivolumab
- Docetaxel
- Gemcitabine
- PD-1 Inhibitor
- TSR-022
Breakdown of trials Gerald Falchook, MD has run
Solid Tumors
Cancer
- Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
- Engineered T-Cell Therapy for Advanced Cancer
- An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma
Lung Cancer
- Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
- An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma
- CAB-ROR2-ADC + PD-1 Inhibitor for Breast Cancer
Pancreatic Cancer
Tumors
- Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
- Engineered T-Cell Therapy for Advanced Cancer
- An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Gerald Falchook, MD specialize in?
Gerald Falchook, MD focuses on Solid Tumors and Cancer. In particular, much of their work with Solid Tumors has involved Stage IV patients, or patients who are Stage III.
Is Gerald Falchook, MD currently recruiting for clinical trials?
Yes, Gerald Falchook, MD is currently recruiting for 11 clinical trials in Denver Colorado. If you're interested in participating, you should apply.
Are there any treatments that Gerald Falchook, MD has studied deeply?
Yes, Gerald Falchook, MD has studied treatments such as Pembrolizumab, Nivolumab, Docetaxel.
What is the best way to schedule an appointment with Gerald Falchook, MD?
Apply for one of the trials that Gerald Falchook, MD is conducting.
What is the office address of Gerald Falchook, MD?
The office of Gerald Falchook, MD is located at: Sarah Cannon Research Institute at HealthONE, Denver, Colorado 80218 United States. This is the address for their practice at the Sarah Cannon Research Institute at HealthONE.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.